CAAP Company: CellAegis' autoRIC® Device Clinically Implemented in Peel-Halton Region
CellAegis autoRIC® Device, which reduces heart damage in ischemic heart disease, is now being clinically implemented in Peel-Halton Region, West of Toronto. The autoRIC® Device is being used to treat all patients having heart attacks, in addition to standard treatment. The FIRST study (Field Implementation of autoRIC Device in STEMI (ST-segment Myocardial Infarction)) is the first clinical implementation of our device across an entire region, and is expected to be the first of many such clinical implementations, as the benefit of Remote Ischemic Conditioning therapy becomes more widely utilized.
For the full press release click here
CAAP Company: KA Imaging Receives $1M to develop low-cost lung screening
July 21, 2016 KITCHENER — A startup developing a low-cost, high-resolution digital X-ray imager to detect lung disease in developing nations has received a $1-million boost.
The new money from federally funded Grand Challenges Canada will help KA Imaging build a prototype and test it in the field in Zambia by the end of the year.
For the full article click here
For the Grand Challenges press release, click here
OBIO Innovation Agenda Leader
OBIO Innovation Agenda Leader
On July 21st, Gail Garland, CEO of OBIO attended the Federal Government's Global Science Excellence Roundtable, part of the Inclusive Innovation Agenda Strategy held in Ottawa.
The ideas generated during the session will be consolidated and presented to Minister Navdeep Bains for consideration as part of the Inclusive Innovation Agenda report.
For the full report, click here
For the Innovation Submission page, click here
CAAP Company: iTP Biomedica Launches BladderPredict, A State-Of-The-Art Diagnostic To Manage Early Stage Bladder Cancer
July 19, 2016 TORONTO – iTP Biomedica Corp., a developer of proprietary whole transcriptome-based cancer diagnostics, today announced the launch of BladderPredict, a groundbreaking next-generation sequencing-based test that will for the first time assist uro-pathologists in assigning disease grade in early stage bladder cancer, and urologists and uro-oncologists in managing the disease.
For the full press release, click here
Pre-CAAP Company: TranQool Featured in Canadian Healthcare Technology Magazine
July 7, 2016 - TranQool. an online platform that matches users with registered Cognitive Behavioural Therapy (CBT) therapists and lets them connect via secure video calls, was featured in Canadian Healthcare Technology magazine.
CAAP Company: Eve Medical featured in Chatelaine
July 6, 2016 - CAAP Company Eve Medical and their CEO, Jessica Ching, are featured in the August issue of Chatelaine.
Synaptive Medical Receives Health Canada Approval For Brightmatter Guide: A Surgical Navigation Solution
July 5, 2016 TORONTO – Synaptive Medical Inc., a company focused on global commercialization of innovative solutions, announced the approval from Health Canada to market BrightMatterTM Guide. This new technology is part of a solution for health care providers that includes informatics, imaging, surgical planning, navigation and advanced optics.
Ontario's Health Technologies Fund now accepting applications
July 4, 2016, TORONTO - Ontario's $20 million Health Technologies Fund (HTF) is open for business.
Announced in May by William Charnetski, Ontario's Chief Health Innovation Strategist, the Fund will support the development of leading, market-ready, made-in-Ontario health technologies by accelerating prototyping, evaluation, adoption and diffusion in the Ontario health care sector.
Sernova Increases Private Placement to $4,200,000
June 29, 2016, London ON – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).
Sernova Announces $2,000,000 First Closing of Private Placement - Due to Oversubscription, Offering Increased to $3,750,000
June 27, 2016 LONDON, ONTARIO Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.
RESI Toronto Receives Two Thumbs Up
June 24, 2016 This year Toronto hosted the inaugural RESI conference on June 23, bringing together hundreds of companies and investors from across the globe in areas of biotech, digital health, medical devices and consumer health.
OBIO Launches Report in the Nation’s Capital
Ottawa, Ontario – June 21, 2016: Ontario Bioscience Innovation Organization (OBIO®) today initiated the Eastern leg of its Provincewide Tour in Ottawa to promote their recently released report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy”.
Sernova Announces Non-brokered Private Placement - Net proceeds to fund collaborations and a US-based clinical trial
June 21, 2016 LONDON, ONTARIO – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.
Canadian Manufacturers & Exporters Article: Valeant manufacturing expansion a Canadian reshoring success
Canadian Manufacturers & Exporters congratulates Valeant Canada on its $27.5 million commitment to expand manufacturing operations in Canada.
For the full article click here
OBIO's Dr. Klaus Fiebig, Senior Director of Strategic Programs, Chosen as Moderater at 2016 MedEdge Summit
June 14, 2016 - OBIO's own Dr. Klaus Fiebig, Senior Director of Strategic Programs, was asked to moderate at this years MedEdge Summit hosted in Richmond Hill.
OBIO CAAP Company: Anges Québec members contribute to $530,000 investment in Ovensa
June 8th, 2016 Montreal – Today Anges Québec announced its members are taking a stake in Ovensa,
a biotechnology company. Members of Anges Québec and Aligo Innovation are joining with private investors to inject $530,000 into this Ontario firm, whose new technology delivers therapeutic molecules through oral administration to targeted human tissue, including the brain—a major medical advance.
For the full press release, click here
OBIO Launches Provincewide Report Tour - First Stop: Silicon Valley North
June 8, 2016. Kitchener. Ontario Bioscience Innovation Organization (OBIO®) today initiated the first leg of its Provincewide Tour to promote their recently released report “How Canada Should be Engaging in a $9 Trillion Dollar Health Economy”.
For the full press release, click here
OBIO CAAP Companies: Highlighted on the Marilyn Denis Show
June 2, 2016 OBIO CAAP companies Eve Medical, Myndtec, and Chipcare were featured on the Marilyn Denis Show this week in a segment focused on Canadian Medical Innovation.
View the video here
CAAP Company: MEDELLA HEALTH Raises $1.4 MILLION
June 2, 2016 Harry Gandhi is the co-founder of Medella Health, a Waterloo-based company developing a smart contact lens that continuously monitors glucose levels (with the information transmitted to a mobile device), is hoping that its contact lens will change the way we approach the disease. The company has raised $1.4 million in funding from 1517 Fund, Fifty Years Fund, Garage Capital, and BDC Capital.
For the full story, click here
OBIO CAAP Company: Perimeter Medical Imaging Receives FDA Clearance for OTIS Optical Tissue Imaging System
May 24, 2016 TORONTO Perimeter Medical Imaging, Inc., an innovative medical imaging company whose mission is to revolutionize tissue removal surgery for surgeons and patients, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for its OTISTM 1.0 Optical Coherence Tomography System.
For the full press release, click here